UCAB focuses on the development of biotherapeutics to treat diseases of high unmet medical need in LMICs. The UCAB organization was established in 2016. The first product (palivizumab) is scheduled to be marketed in 2023. At this stage, business development is an important focus for UCAB. 

Our current portfolio includes: